Sunshine Biopharma (SBFM) Accounts Payables (2010 - 2026)

Sunshine Biopharma's Accounts Payables history runs 16 years deep, the most recent figure standing at $5.1 million for Q1 2026.

• Quarterly Accounts Payables rose 1.6% year-over-year to $5.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.1 million (up 1.6% YoY) and the FY2025 annual result came in at $5.7 million, up 2.19% from the prior year.
• Accounts Payables was $5.1 million for Q1 2026 at Sunshine Biopharma, down from $5.7 million in the prior quarter.
• Across five years, Accounts Payables topped out at $6.1 million in Q3 2025 and bottomed at $95234.0 in Q1 2022.
• A 5-year average of $3.4 million and a median of $3.6 million in 2024 frame the typical range for Accounts Payables.
• Peak annual rise in Accounts Payables reached 6426.94% in 2022, while the deepest fall reached 35.9% in 2022.
• Sunshine Biopharma's Accounts Payables stood at $2.8 million in 2022, then fell by 7.75% to $2.6 million in 2023, then surged by 114.39% to $5.5 million in 2024, then gained by 2.19% to $5.7 million in 2025, then slipped by 9.88% to $5.1 million in 2026.
• Business Quant data shows SBFM's Accounts Payables at $5.1 million in Q1 2026, $5.7 million in Q4 2025, and $6.1 million in Q3 2025.